WO2008120813A1 - ジペプチジルペプチダーゼ４阻害化合物と甘味料との併用 - Google Patents

ジペプチジルペプチダーゼ４阻害化合物と甘味料との併用 Download PDF

Info

Publication number
WO2008120813A1
WO2008120813A1 PCT/JP2008/056678 JP2008056678W WO2008120813A1 WO 2008120813 A1 WO2008120813 A1 WO 2008120813A1 JP 2008056678 W JP2008056678 W JP 2008056678W WO 2008120813 A1 WO2008120813 A1 WO 2008120813A1
Authority
WO
WIPO (PCT)
Prior art keywords
sweetener
inhibitor compound
dipeptidyl peptidase
combined use
effect
Prior art date
Application number
PCT/JP2008/056678
Other languages
English (en)
French (fr)
Inventor
Masaharu Shiotani
Tomomi Ishihara
Chiaki Matsushita
Original Assignee
Mitsubishi Tanabe Pharma Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corporation filed Critical Mitsubishi Tanabe Pharma Corporation
Priority to AU2008233548A priority Critical patent/AU2008233548B2/en
Priority to US12/594,568 priority patent/US8927504B2/en
Priority to KR1020097022913A priority patent/KR101361427B1/ko
Priority to ES08739785.7T priority patent/ES2529149T3/es
Priority to JP2009507560A priority patent/JP5616630B2/ja
Priority to CN2008800111647A priority patent/CN101652147B/zh
Priority to EP08739785.7A priority patent/EP2143443B1/en
Priority to CA2682736A priority patent/CA2682736C/en
Publication of WO2008120813A1 publication Critical patent/WO2008120813A1/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

　優れた抗肥満効果（体脂肪減少効果　及び/または　体脂肪減少効果）を発揮する新規な治療もしくは予防方法、医薬組成物、及びそれらの使用を提供する。 　ジペプチジルペプチダーゼ４阻害化合物とＧＬＰ－１分泌促進作用を有する甘味料とを組み合わせてなる医薬組成物、並びに医薬の製造におけるその使用。また、肥満の症状を有する患者に、（ａ）ジペプチジルペプチダーゼ４阻害化合物及び（ｂ）ＧＬＰ－１分泌促進作用を有する甘味料を有効量投与することを特徴とする肥満の治療又は予防方法。
PCT/JP2008/056678 2007-04-03 2008-04-03 ジペプチジルペプチダーゼ４阻害化合物と甘味料との併用 WO2008120813A1 (ja)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU2008233548A AU2008233548B2 (en) 2007-04-03 2008-04-03 Combined use of dipeptidyl peptidase IV inhibitor compound and sweetener
US12/594,568 US8927504B2 (en) 2007-04-03 2008-04-03 Combined use of dipeptidyl peptidase 4 inhibitor and sweetener
KR1020097022913A KR101361427B1 (ko) 2007-04-03 2008-04-03 디펩티딜 펩티다아제 4 저해 화합물과 감미료와의 병용
ES08739785.7T ES2529149T3 (es) 2007-04-03 2008-04-03 Una combinación de inhibidor de dipeptidil peptidasa IV y edulcorante para uso en el tratamiento de la obesidad
JP2009507560A JP5616630B2 (ja) 2007-04-03 2008-04-03 ジペプチジルペプチダーゼ４阻害化合物と甘味料との併用
CN2008800111647A CN101652147B (zh) 2007-04-03 2008-04-03 二肽基肽酶iv抑制化合物和甜味剂的并用
EP08739785.7A EP2143443B1 (en) 2007-04-03 2008-04-03 A combination of dipeptidyl peptidase iv inhibitor and sweetener for use in the treatment of obesity
CA2682736A CA2682736C (en) 2007-04-03 2008-04-03 Combined use of dipeptidyl peptidase 4 inhibitor and sweetener

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US90747107P 2007-04-03 2007-04-03
JP2007097079 2007-04-03
US60/907,471 2007-04-03
JP2007-097079 2007-04-03

Publications (1)

Publication Number Publication Date
WO2008120813A1 true WO2008120813A1 (ja) 2008-10-09

Family

ID=39808393

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/056678 WO2008120813A1 (ja) 2007-04-03 2008-04-03 ジペプチジルペプチダーゼ４阻害化合物と甘味料との併用

Country Status (9)

Country Link
US (1) US8927504B2 (ja)
EP (1) EP2143443B1 (ja)
JP (2) JP5616630B2 (ja)
KR (2) KR20120030570A (ja)
CN (2) CN101652147B (ja)
AU (1) AU2008233548B2 (ja)
CA (1) CA2682736C (ja)
ES (1) ES2529149T3 (ja)
WO (1) WO2008120813A1 (ja)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010039124A1 (en) * 2008-09-30 2010-04-08 Mitsubishi Tanabe Pharma Corporation Benzenesulfonic acid salt compounds
WO2011068150A1 (ja) * 2009-12-04 2011-06-09 株式会社東洋新薬 グルカゴン様ペプチド－１分泌促進剤
JP2011173798A (ja) * 2010-02-23 2011-09-08 Yakult Honsha Co Ltd 腸間膜脂肪低減剤
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
JP2011207834A (ja) * 2010-03-30 2011-10-20 Shizuokaken Koritsu Daigaku Hojin Ｇｐｒ４３陽性・腸内分泌細胞増加促進剤
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
WO2011161030A1 (de) 2010-06-21 2011-12-29 Sanofi Heterocyclisch substituierte methoxyphenylderivate mit oxogruppe, verfahren zu ihrer herstellung und ihre verwendung als gpr40 rezeptor modulatoren
WO2012004270A1 (de) 2010-07-05 2012-01-12 Sanofi Spirocyclisch substituierte 1,3-propandioxidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2012004269A1 (de) 2010-07-05 2012-01-12 Sanofi ( 2 -aryloxy -acetylamino) - phenyl - propionsäurederivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2012010413A1 (de) 2010-07-05 2012-01-26 Sanofi Aryloxy-alkylen-substituierte hydroxy-phenyl-hexinsäuren, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
JP2012236849A (ja) * 2007-04-03 2012-12-06 Mitsubishi Tanabe Pharma Corp ジペプチジルペプチダーゼ４阻害化合物と甘味料との併用
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP2013525471A (ja) * 2010-05-05 2013-06-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 併用療法
WO2014064215A1 (en) 2012-10-24 2014-05-01 INSERM (Institut National de la Santé et de la Recherche Médicale) TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING β-CELL SURVIVAL
WO2016151018A1 (en) 2015-03-24 2016-09-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment of diabetes
WO2021153718A1 (ja) * 2020-01-31 2021-08-05 国立大学法人京都大学 線維芽細胞増殖因子２１誘導剤、及びアルコール嗜好性又は単純糖質嗜好性を抑制するための組成物

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP2540725A1 (de) 2006-05-04 2013-01-02 Boehringer Ingelheim International GmbH Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20090938A1 (es) 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
RU2011113823A (ru) 2008-09-10 2012-10-20 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) Комбинированная терапия, предназначенная для лечения диабета и связанных с ним состояний
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
JP2012512848A (ja) 2008-12-23 2012-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 有機化合物の塩の形態
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
NZ594487A (en) 2009-02-13 2013-11-29 Boehringer Ingelheim Int Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
NZ599298A (en) 2009-11-27 2014-11-28 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
EP3725325B1 (en) 2010-06-24 2023-05-31 Boehringer Ingelheim International GmbH Diabetes therapy
CA2815024A1 (en) 2010-10-19 2012-04-26 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
DK2731947T3 (en) 2011-07-15 2019-04-23 Boehringer Ingelheim Int SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
WO2016044756A1 (en) * 2014-09-18 2016-03-24 The Trustees Of Columbia University In The City Of New York A neural substrate for sugar preference
CA3022202A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
JP6842072B2 (ja) * 2019-03-07 2021-03-17 物産フードサイエンス株式会社 エガセラ属細菌の菌数抑制剤
JP6765090B2 (ja) * 2019-05-14 2020-10-07 株式会社東洋新薬 黒生姜含有組成物

Citations (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6260369B2 (ja) 1982-11-04 1987-12-16 Meiji Seika Co
JPH0665080A (ja) 1992-03-10 1994-03-08 Godo Shiyusei Kk α−グルコシダ−ゼ阻害剤を含有する、過血糖付随疾患の予防・治療剤、および保健食
WO1995015309A1 (en) 1993-12-03 1995-06-08 Ferring B.V. Dp-iv-serine protease inhibitors
WO1997040832A1 (de) 1996-04-25 1997-11-06 Probiodrug Gesellschaft für Arzneimittelforschung mbH Verwendung von dipeptidyl peptidase iv effektoren zur senkung des blutglukosespiegels in säugern
WO1998019998A2 (en) 1996-11-07 1998-05-14 Novartis Ag N-substituted 2-cyanopyrrolidines
JPH10290681A (ja) 1997-04-18 1998-11-04 Suntory Ltd 抗肥満作用を有する飲食品
WO1999061431A1 (de) 1998-05-28 1999-12-02 Probiodrug Gesellschaft für Arzneimittelforschung mbH Neue effektoren von dipeptidylpeptidase iv
WO2000034241A1 (en) 1998-12-10 2000-06-15 Novartis Ag N-substituted 2-cyanopyrrolidines
US6107317A (en) 1999-06-24 2000-08-22 Novartis Ag N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6110949A (en) 1999-06-24 2000-08-29 Novartis Ag N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6172081B1 (en) 1999-06-24 2001-01-09 Novartis Ag Tetrahydroisoquinoline 3-carboxamide derivatives
WO2001040180A2 (en) 1999-11-30 2001-06-07 Ferring Bv N-substituted 2-cyanopyrrolidines and their use as antidiabetic agents
WO2001068603A2 (en) 2000-03-10 2001-09-20 Bristol-Myers Squibb Co. Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl iv, processes for their preparation, and their use
WO2001081337A1 (en) 2000-04-26 2001-11-01 Ferring B.V. Inhibitors of dipeptidyl peptidase iv
WO2001081304A1 (en) 2000-04-26 2001-11-01 Ferring Bv Inhibitors of dipeptidyl peptidase iv
WO2001096295A2 (en) 2000-06-13 2001-12-20 Novartis Ag 2-cyanopyrrolidine derivatives and their use as medicaments
WO2002014271A1 (fr) 2000-08-10 2002-02-21 Mitsubishi Pharma Corporation Dérivés de proline et leur utilisation comme médicaments
WO2002030891A1 (fr) 2000-10-06 2002-04-18 Tanabe Seiyaku Co., Ltd. Composes aliphatiques azotes a noyau a cinq elements
WO2002051836A1 (fr) 2000-12-27 2002-07-04 Kyowa Hakko Kogyo Co., Ltd. Inhibiteur de dipeptidyl peptidase iv
JP2002265439A (ja) 2001-03-08 2002-09-18 Mitsubishi Pharma Corp シアノピロリジン誘導体およびその医薬用途
WO2002076450A1 (en) 2001-03-27 2002-10-03 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2002083128A1 (en) 2001-04-12 2002-10-24 Bristol-Myers Squibb Company 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase iv and method
WO2003000250A1 (en) 2001-06-25 2003-01-03 Ferring Bv 3-fluoro-pyrrolidines as antidiabetic agents
WO2003002553A2 (en) 2001-06-27 2003-01-09 Smithkline Beecham Corporation Fluoropyrrolidines as dipeptidyl peptidase inhibitors
WO2003002530A2 (en) 2001-06-27 2003-01-09 Smithkline Beecham Corporation Pyrrolidines as dipeptidyl peptidase inhibitors
WO2003002531A2 (en) 2001-06-27 2003-01-09 Smithkline Beecham Corporation Fluoropyrrolidines as dipeptidyl peptidase inhibitors
WO2003004498A1 (en) 2001-07-06 2003-01-16 Merck & Co., Inc. Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2003015775A1 (en) 2001-08-17 2003-02-27 Probiodrug Ag New dipeptidyl peptidase iv inhibitors and their uses for lowering blood pressure levels
WO2003024942A1 (fr) 2001-09-14 2003-03-27 Mitsubishi Pharma Corporation Derive thiazolidine et son utilisation medicamenteuse
WO2003035057A1 (en) 2001-10-23 2003-05-01 Ferring B.V. Inhibitors of dipeptidyl peptidase iv
WO2004009544A1 (ja) 2002-07-23 2004-01-29 Yamanouchi Pharmaceutical Co., Ltd. 2-シアノ−４−フルオロピロリジン誘導体又はその塩
WO2004020407A1 (ja) 2002-08-29 2004-03-11 Taisho Pharmaceutical Co.,Ltd. ４−フルオロ−２−シアノピロリジン誘導体ベンゼンスルホン酸塩
WO2004067509A1 (ja) 2003-01-31 2004-08-12 Sanwa Kagaku Kenkyusho Co., Ltd. ジペプチジルペプチダーゼivを阻害する化合物
WO2004087053A2 (en) 2003-03-25 2004-10-14 Syrrx, Inc. Dipeptidyl peptidase inhibitors
WO2004103993A1 (en) 2003-05-14 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
WO2005012249A2 (en) 2003-08-01 2005-02-10 Bristol-Myers Squibb Company Adamantyglycine- based inhibitors of dipeptidyl peptidase iv for the treatment of diabetes
WO2005026148A1 (en) 2003-09-08 2005-03-24 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
WO2005030751A2 (en) 2003-09-08 2005-04-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2005036990A1 (en) 2003-09-30 2005-04-28 Tiense Suikerraffinaderij N.V. Composition for prevention, inhibition and treatment of obesity and related diseases
WO2005037828A1 (en) 2003-10-20 2005-04-28 Lg Life Sciences Ltd. Novel inhibitors of dpp-iv, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent
JP2005170792A (ja) 2002-11-22 2005-06-30 Mitsubishi Pharma Corp Ｌ−プロリン誘導体およびその医薬としての用途。
WO2005075421A1 (ja) 2004-02-05 2005-08-18 Kyorin Pharmaceutical Co., Ltd. ビシクロエステル誘導体
WO2005075426A1 (en) 2004-02-03 2005-08-18 Glenmark Pharmaceuticals Ltd. Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof
WO2005077900A1 (ja) 2004-02-18 2005-08-25 Kyorin Pharmaceutical Co., Ltd. ビシクロアミド誘導体
WO2005082847A1 (ja) 2004-02-27 2005-09-09 Kyorin Pharmaceutical Co., Ltd. ビシクロ誘導体
WO2005095381A1 (en) 2004-03-15 2005-10-13 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2006088129A1 (ja) 2005-02-18 2006-08-24 Mitsubishi Pharma Corporation プロリン誘導体の塩、またはその溶媒和物、及びその製造方法
WO2006090244A1 (en) 2005-02-22 2006-08-31 Glenmark Pharmaceuticals S.A. New adamantane derivatives as dipeptidyl, peptidase iv inhibitors, processes for their preparation, and pharmaceutical compositions containing them
WO2006104356A1 (en) 2005-04-01 2006-10-05 Lg Life Sciences, Ltd. Dipeptidyl peptidase-iv inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent
WO2006116157A2 (en) 2005-04-22 2006-11-02 Alantos Pharmaceuticals Holding, Inc. Dipeptidyl peptidase-iv inhibitors
JP2007001946A (ja) * 2005-06-24 2007-01-11 Ono Pharmaceut Co Ltd ピロリジン誘導体
JP2007504230A (ja) * 2003-09-02 2007-03-01 メルク　エンド　カムパニー　インコーポレーテッド ジペプチジルペプチダーゼ−ｉｖ阻害剤のリン酸塩の新規結晶性形態

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030031772A1 (en) * 2001-03-28 2003-02-13 Zehner Lee R. Mixtures of fructose and lactose as a low-calorie bulk sweetener with reduced glyemic index
US6710040B1 (en) * 2002-06-04 2004-03-23 Pfizer Inc. Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors
US20040087514A1 (en) * 2002-09-06 2004-05-06 Hughes Thomas E Nutritional compositions
KR20120030570A (ko) * 2007-04-03 2012-03-28 미쓰비시 타나베 파마 코퍼레이션 디펩티딜 펩티다아제 4 저해 화합물과 감미료와의 병용

Patent Citations (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6260369B2 (ja) 1982-11-04 1987-12-16 Meiji Seika Co
JPH0665080A (ja) 1992-03-10 1994-03-08 Godo Shiyusei Kk α−グルコシダ−ゼ阻害剤を含有する、過血糖付随疾患の予防・治療剤、および保健食
WO1995015309A1 (en) 1993-12-03 1995-06-08 Ferring B.V. Dp-iv-serine protease inhibitors
WO1997040832A1 (de) 1996-04-25 1997-11-06 Probiodrug Gesellschaft für Arzneimittelforschung mbH Verwendung von dipeptidyl peptidase iv effektoren zur senkung des blutglukosespiegels in säugern
WO1998019998A2 (en) 1996-11-07 1998-05-14 Novartis Ag N-substituted 2-cyanopyrrolidines
JPH10290681A (ja) 1997-04-18 1998-11-04 Suntory Ltd 抗肥満作用を有する飲食品
EP1082314A1 (de) 1998-05-28 2001-03-14 Probiodrug Gesellschaft für Arzneimittelforschung mbH Neue effektoren von dipeptidylpeptidase iv
WO1999061431A1 (de) 1998-05-28 1999-12-02 Probiodrug Gesellschaft für Arzneimittelforschung mbH Neue effektoren von dipeptidylpeptidase iv
WO2000034241A1 (en) 1998-12-10 2000-06-15 Novartis Ag N-substituted 2-cyanopyrrolidines
US6107317A (en) 1999-06-24 2000-08-22 Novartis Ag N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6172081B1 (en) 1999-06-24 2001-01-09 Novartis Ag Tetrahydroisoquinoline 3-carboxamide derivatives
US6110949A (en) 1999-06-24 2000-08-29 Novartis Ag N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
WO2001040180A2 (en) 1999-11-30 2001-06-07 Ferring Bv N-substituted 2-cyanopyrrolidines and their use as antidiabetic agents
WO2001068603A2 (en) 2000-03-10 2001-09-20 Bristol-Myers Squibb Co. Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl iv, processes for their preparation, and their use
WO2001081337A1 (en) 2000-04-26 2001-11-01 Ferring B.V. Inhibitors of dipeptidyl peptidase iv
WO2001081304A1 (en) 2000-04-26 2001-11-01 Ferring Bv Inhibitors of dipeptidyl peptidase iv
WO2001096295A2 (en) 2000-06-13 2001-12-20 Novartis Ag 2-cyanopyrrolidine derivatives and their use as medicaments
WO2002014271A1 (fr) 2000-08-10 2002-02-21 Mitsubishi Pharma Corporation Dérivés de proline et leur utilisation comme médicaments
US7060722B2 (en) 2000-08-10 2006-06-13 Mitsubishi Pharma Corporation Proline derivatives and use thereof as drugs
US7074794B2 (en) 2000-08-10 2006-07-11 Mitsubishi Pharma Corporation Proline derivatives and the use thereof as drugs
US6849622B2 (en) 2000-10-06 2005-02-01 Tanabe Seiyaku Co., Ltd. Aliphatic nitrogenous five-membered ring compounds
WO2002030891A1 (fr) 2000-10-06 2002-04-18 Tanabe Seiyaku Co., Ltd. Composes aliphatiques azotes a noyau a cinq elements
WO2002030890A1 (fr) 2000-10-06 2002-04-18 Tanabe Seiyaku Co., Ltd. Composes azotes a noyau a cinq elements
US7138397B2 (en) 2000-10-06 2006-11-21 Tanabe Seiyaku Co., Ltd. Nitrogenous 5-membered ring compounds
WO2002051836A1 (fr) 2000-12-27 2002-07-04 Kyowa Hakko Kogyo Co., Ltd. Inhibiteur de dipeptidyl peptidase iv
JP2002265439A (ja) 2001-03-08 2002-09-18 Mitsubishi Pharma Corp シアノピロリジン誘導体およびその医薬用途
WO2002076450A1 (en) 2001-03-27 2002-10-03 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2002083128A1 (en) 2001-04-12 2002-10-24 Bristol-Myers Squibb Company 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase iv and method
WO2003000250A1 (en) 2001-06-25 2003-01-03 Ferring Bv 3-fluoro-pyrrolidines as antidiabetic agents
WO2003002531A2 (en) 2001-06-27 2003-01-09 Smithkline Beecham Corporation Fluoropyrrolidines as dipeptidyl peptidase inhibitors
WO2003002530A2 (en) 2001-06-27 2003-01-09 Smithkline Beecham Corporation Pyrrolidines as dipeptidyl peptidase inhibitors
WO2003002553A2 (en) 2001-06-27 2003-01-09 Smithkline Beecham Corporation Fluoropyrrolidines as dipeptidyl peptidase inhibitors
WO2003004498A1 (en) 2001-07-06 2003-01-16 Merck & Co., Inc. Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2003015775A1 (en) 2001-08-17 2003-02-27 Probiodrug Ag New dipeptidyl peptidase iv inhibitors and their uses for lowering blood pressure levels
WO2003024942A1 (fr) 2001-09-14 2003-03-27 Mitsubishi Pharma Corporation Derive thiazolidine et son utilisation medicamenteuse
WO2003035057A1 (en) 2001-10-23 2003-05-01 Ferring B.V. Inhibitors of dipeptidyl peptidase iv
WO2004009544A1 (ja) 2002-07-23 2004-01-29 Yamanouchi Pharmaceutical Co., Ltd. 2-シアノ−４−フルオロピロリジン誘導体又はその塩
WO2004020407A1 (ja) 2002-08-29 2004-03-11 Taisho Pharmaceutical Co.,Ltd. ４−フルオロ−２−シアノピロリジン誘導体ベンゼンスルホン酸塩
JP2005170792A (ja) 2002-11-22 2005-06-30 Mitsubishi Pharma Corp Ｌ−プロリン誘導体およびその医薬としての用途。
WO2004067509A1 (ja) 2003-01-31 2004-08-12 Sanwa Kagaku Kenkyusho Co., Ltd. ジペプチジルペプチダーゼivを阻害する化合物
WO2004087053A2 (en) 2003-03-25 2004-10-14 Syrrx, Inc. Dipeptidyl peptidase inhibitors
WO2004103993A1 (en) 2003-05-14 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
WO2005012249A2 (en) 2003-08-01 2005-02-10 Bristol-Myers Squibb Company Adamantyglycine- based inhibitors of dipeptidyl peptidase iv for the treatment of diabetes
JP2007504230A (ja) * 2003-09-02 2007-03-01 メルク　エンド　カムパニー　インコーポレーテッド ジペプチジルペプチダーゼ−ｉｖ阻害剤のリン酸塩の新規結晶性形態
WO2005026148A1 (en) 2003-09-08 2005-03-24 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
WO2005030751A2 (en) 2003-09-08 2005-04-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2005036990A1 (en) 2003-09-30 2005-04-28 Tiense Suikerraffinaderij N.V. Composition for prevention, inhibition and treatment of obesity and related diseases
WO2005037828A1 (en) 2003-10-20 2005-04-28 Lg Life Sciences Ltd. Novel inhibitors of dpp-iv, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent
WO2005075426A1 (en) 2004-02-03 2005-08-18 Glenmark Pharmaceuticals Ltd. Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof
WO2005075421A1 (ja) 2004-02-05 2005-08-18 Kyorin Pharmaceutical Co., Ltd. ビシクロエステル誘導体
WO2005077900A1 (ja) 2004-02-18 2005-08-25 Kyorin Pharmaceutical Co., Ltd. ビシクロアミド誘導体
WO2005082847A1 (ja) 2004-02-27 2005-09-09 Kyorin Pharmaceutical Co., Ltd. ビシクロ誘導体
WO2005095381A1 (en) 2004-03-15 2005-10-13 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2006088129A1 (ja) 2005-02-18 2006-08-24 Mitsubishi Pharma Corporation プロリン誘導体の塩、またはその溶媒和物、及びその製造方法
WO2006090244A1 (en) 2005-02-22 2006-08-31 Glenmark Pharmaceuticals S.A. New adamantane derivatives as dipeptidyl, peptidase iv inhibitors, processes for their preparation, and pharmaceutical compositions containing them
WO2006104356A1 (en) 2005-04-01 2006-10-05 Lg Life Sciences, Ltd. Dipeptidyl peptidase-iv inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent
WO2006116157A2 (en) 2005-04-22 2006-11-02 Alantos Pharmaceuticals Holding, Inc. Dipeptidyl peptidase-iv inhibitors
JP2007001946A (ja) * 2005-06-24 2007-01-11 Ono Pharmaceut Co Ltd ピロリジン誘導体

Non-Patent Citations (19)

* Cited by examiner, † Cited by third party
Title
2006 NEN NEWS RELEASE: "Beikoku Merck-sha ga, Atarashii Keiko Tonyobyo Chiryoyaku Sitagliptin ni Kansuru Dai III-so Rinsho Shiken no Seiseki o Beikoku Tonyobyo Gakkai nite Happyo (Dai 2 Ho)", ONO PHARMACEUTICAL CO., LTD., 14 June 2006 (2006-06-14), XP008117418, Retrieved from the Internet <URL:http://www.ono.co.jp/jpnw/news/pdf/2006-n06_0614.pdf> *
AUGUSTYNS ET AL., EXPERT OPIN. THER. PATENTS, vol. 13, 2003, pages 499 - 510
CAMPBELL, ANN. PHARMACOTHER., vol. 41, 2007, pages 51 - 60
CANI ET AL., BRITISH JOURNAL OF NUTRITION, vol. 92, 2004, pages 521 - 526
CANI ET AL., BRITISH JOURNAL OF NUTRITION, vol. 92, 2004, pages 52L - 526
CANI ET AL., DIABETES, vol. 55, 2006, pages 1484 - 1490
CANI ET AL., JOURNAL OF ENDOCRINOLOGY, vol. 185, 2005, pages 457 - 465
CANI ET AL., OBESITY, vol. 13, 2005, pages 1000 - 1007
DEFRONZO ET AL., DIABETES CARE, vol. 28, no. 5, 2005, pages 1092 - 100
ILTZ, J. L. ET AL., CLIN. THER., vol. 28, no. 5, 2006, pages 652 - 65
ILTZ, J.L. ET AL., CLIN. THER., vol. 28, no. 5, 2006, pages 652 - 65
INT. J. OBES., vol. 30, 2006, pages 1332 - 1340
MACK ET AL., INT. J. OBES., vol. 30, no. 9, 2006, pages 1332 - 40
OBESITY RES., vol. 13, 2005, pages 1000 - 1007
See also references of EP2143443A4 *
SHIMA ET AL., ACTA ENDOCRINOLOGICA, vol. 123, 1990, pages 464 - 470
TOKUNAGA ET AL., J. NUTRI. SCI. VITAMINOL., vol. 32, 1986, pages 111 - 121
WATANABE ET AL., EXPERIENTIA, vol. 43, 1987, pages 400 - 401
ZANDER ET AL., LANCET, vol. 359, 2002, pages 824 - 830

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012236849A (ja) * 2007-04-03 2012-12-06 Mitsubishi Tanabe Pharma Corp ジペプチジルペプチダーゼ４阻害化合物と甘味料との併用
WO2010039124A1 (en) * 2008-09-30 2010-04-08 Mitsubishi Tanabe Pharma Corporation Benzenesulfonic acid salt compounds
WO2011068150A1 (ja) * 2009-12-04 2011-06-09 株式会社東洋新薬 グルカゴン様ペプチド－１分泌促進剤
JP5721232B2 (ja) * 2009-12-04 2015-05-20 株式会社東洋新薬 グルカゴン様ペプチド−１分泌促進剤
JP2011173798A (ja) * 2010-02-23 2011-09-08 Yakult Honsha Co Ltd 腸間膜脂肪低減剤
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
JP2011207834A (ja) * 2010-03-30 2011-10-20 Shizuokaken Koritsu Daigaku Hojin Ｇｐｒ４３陽性・腸内分泌細胞増加促進剤
JP2013525471A (ja) * 2010-05-05 2013-06-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 併用療法
JP2015145435A (ja) * 2010-05-05 2015-08-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 併用療法
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
WO2011161030A1 (de) 2010-06-21 2011-12-29 Sanofi Heterocyclisch substituierte methoxyphenylderivate mit oxogruppe, verfahren zu ihrer herstellung und ihre verwendung als gpr40 rezeptor modulatoren
WO2012004269A1 (de) 2010-07-05 2012-01-12 Sanofi ( 2 -aryloxy -acetylamino) - phenyl - propionsäurederivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2012010413A1 (de) 2010-07-05 2012-01-26 Sanofi Aryloxy-alkylen-substituierte hydroxy-phenyl-hexinsäuren, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2012004270A1 (de) 2010-07-05 2012-01-12 Sanofi Spirocyclisch substituierte 1,3-propandioxidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2014064215A1 (en) 2012-10-24 2014-05-01 INSERM (Institut National de la Santé et de la Recherche Médicale) TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING β-CELL SURVIVAL
WO2016151018A1 (en) 2015-03-24 2016-09-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment of diabetes
WO2021153718A1 (ja) * 2020-01-31 2021-08-05 国立大学法人京都大学 線維芽細胞増殖因子２１誘導剤、及びアルコール嗜好性又は単純糖質嗜好性を抑制するための組成物

Also Published As

Publication number Publication date
ES2529149T3 (es) 2015-02-17
EP2143443B1 (en) 2014-11-19
KR20120030570A (ko) 2012-03-28
KR101361427B1 (ko) 2014-02-10
CN101652147A (zh) 2010-02-17
CN101652147B (zh) 2013-07-24
CN103330939A (zh) 2013-10-02
EP2143443A4 (en) 2012-04-18
JP5616630B2 (ja) 2014-10-29
US20100113382A1 (en) 2010-05-06
EP2143443A1 (en) 2010-01-13
CA2682736C (en) 2013-07-09
CA2682736A1 (en) 2008-10-09
AU2008233548B2 (en) 2011-12-01
JPWO2008120813A1 (ja) 2010-07-15
US8927504B2 (en) 2015-01-06
JP2012236849A (ja) 2012-12-06
KR20090127946A (ko) 2009-12-14
AU2008233548A1 (en) 2008-10-09

Similar Documents

Publication Publication Date Title
WO2008120813A1 (ja) ジペプチジルペプチダーゼ４阻害化合物と甘味料との併用
NZ608829A (en) Pharmaceutical composition comprising an sglt2-inhibitor, methods for treating and uses thereof
MX2012000488A (es) Terapia de combinacion para el tratamiento de la diabetes.
TN2009000177A1 (en) Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions
UA102429C2 (ru) Фармацевтическая композиция, которая включает ингибитор sglt-2, ингибитор дпп-iv и другой антидиабетический агент, и ее применение
MX2013004699A (es) Combinaciones farmaceuticas para el tratamiento de trastornos metabolicos.
MX2012006734A (es) Tiazolidinadionas moderadoras de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de obesidad y otras enfermedades metabolicas.
MX366175B (es) Composiciones fosfolipidicas terapeuticas concentradas.
MX2012006744A (es) Tiazolidinadionas reguladores de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de diabetes mellitus y otras enfermedades metabolicas.
MY151048A (en) Use of flibanserin for the treatment of post-menopausal sexual desire disorders
WO2011014255A8 (en) Treatment of crohn&#39;s disease with laquinimod
NZ594044A (en) Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
WO2012170899A3 (en) Pharmaceutical compositions containing proteases and methods for the treatment of lysosomal storage diseases
WO2010080756A3 (en) Harmine derivatives for reducing body weight
WO2005097103A3 (en) Diabetes and metabolic syndrome therapy utilizing cathepsin b inhibitors
WO2007100561A3 (en) Use of dha and ara in the preparation of a composition for preventing or treating obesity
WO2009140269A3 (en) Recombinant human cc10 and compositions thereof for use in the treatment of nasal rhinitis
WO2008012796A3 (en) Pharmaceutical compositions comprising ccl2 and use of same for the treatment of inflammation
WO2010011926A3 (en) A novel betaine cocrystal of epalrestat
NZ595364A (en) TISSUE KALLIKREIN FOR THE TREATMENT OF PANCREATIC beta-CELL DYSFUNCTION
WO2007140299A3 (en) Use of ixabepilone in combination with cyp3a4 inhibitors for pharmaceuticals
MY156174A (en) 4-(1,2,4-dioxazol-3-yl)benzamides for the treatment of diabetes and obesity
WO2009019693A3 (en) Analgesic effect of jasmonate derivatives
TW200731976A (en) Use of tiotropium salts in the treatment of moderate persistent asthma
MX2008001506A (es) Uso de sales de triotropio en el tratamiento de asma severa persistente.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880011164.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08739785

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009507560

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2682736

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12594568

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008233548

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 20097022913

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008739785

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008233548

Country of ref document: AU

Date of ref document: 20080403

Kind code of ref document: A